The United Kingdom and the United States have announced a landmark commercial pact that will keep zero tariffs on British pharmaceutical products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase spending on medicines through the National Health Service (NHS). This move secures that duties on these crucial products will remain at zero for a timeframe of the next three years.
This agreement follows recent statements to dramatically increase tariffs on patented pharmaceutical products, with increases discussed as high as 100%.
"This arrangement with the UK strengthens the international landscape for innovative medicines and brings much-needed fairness to American-British medicine commerce," a release said.
Economic Importance
Drugs constitute one of the the United Kingdom's most significant goods shipped to the America, which is by far the largest buyer for leading UK drugmakers.
Export figures indicate that in the 12 months leading up to last September, the UK sold pharmaceutical products worth billions to the US. This amount made up a significant portion of British export trade in that span.
"This guarantee secures work, increases investment and paves the way for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The pact entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds exceeded twenty percent.
Industry Background
This agreement takes place against a protracted tension between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were exacerbated by claims that American customers were paying several times more for the same drugs than people in the other developed nations.
Recently, several large manufacturing plans in the UK have been halted or cancelled, while major funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the last ten years.
